NextGen Bio
Filter News
Found 7,366 articles
-
Initial Therapeutics Names Peter DiLaura as CEO
4/18/2024
Initial Therapeutics Inc. has appointed Peter DiLaura as President and Chief Executive Officer and a member of the company's Board of Directors, effective immediately.
-
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
4/3/2024
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing.
-
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
3/25/2024
Apogee Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.
-
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
3/7/2024
Apogee Therapeutics, Inc. announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price per share of $62.00.
-
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
3/5/2024
Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications, reported pipeline highlights and fourth quarter and full year 2023 financial results.
-
Bonum Therapeutics to Present Poster on Lead Program at AACR 2024
3/5/2024
Bonum Therapeutics announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic.
-
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - March 05, 2024
3/5/2024
Apogee Therapeutics, Inc. announced that it has commenced an underwritten public offering of approximately $350.0 million of shares of its common stock.
-
Rapport Therapeutics Appoints Chief People Officer
2/28/2024
Rapport Therapeutics, Inc. today announced the appointment of Kathy Wilkinson as Chief People Officer.
-
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors
1/16/2024
Rapport Therapeutics, Inc. announced the appointment of Terry-Ann Burrell to its Board of Directors.
-
The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.
-
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.
-
Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace's tenth annual NextGen list of the hottest new life sciences companies.
-
Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
12/15/2023
Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio.
-
Interviews can be difficult in any field, but especially in a competitive industry like the life sciences. Read on to discover the best way to answer salary interview questions in our guide.
-
Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
12/10/2023
Chroma Medicine, Inc. presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor T cells at the American Society of Hematology 65th Annual Meeting in San Diego.
-
Odyssey Therapeutics Announces $101 Million Series C Financing
12/5/2023
Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics with the goal of providing transformative medicines for large numbers of patients in need and several of these molecules have the potential to enter the clinic in the next 12 months.
-
Aro Biotherapeutics Secures $41.5M Series B Financing
11/28/2023
Aro Biotherapeutics today announced it has secured $41.5M in a Series B funding round.
-
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
11/28/2023
Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
-
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
11/21/2023
Epic Bio announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.
-
Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
11/11/2023
Chroma Medicine, Inc. presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association Scientific Sessions, held November 11-13 in Philadelphia.